-
-
-
-
-
-
-
Myriad Genetics (MYGN) Misses Q1 EPS by 2c ; Offers Guidance
-
-
-
-
-
-
-
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance
-
-
-
-
-
-
-
Myriad Genetics (MYGN) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY25 Guidance
-
-
-
-
-
-
-
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance
-
-
-
-
-
-
-
Diligent Announces Market Insights Reporting Powered by S&P Global Market Intelligence, Giving Directors and Executives Unrivaled Financial and Risk Insights
-
-
-
-
-
-
-
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
-
-
-
-
-
-
-
Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA
-
1,225,841 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

